Form 4: Dyne Therapeutics Officer Sells Shares for Tax Withholding

Dyne Therapeutics Chief Medical Officer Douglas Kerr sold company stock to cover tax obligations related to vested restricted stock units.

Summary

• Douglas Kerr, Chief Medical Officer at Dyne Therapeutics, Inc., reported a transaction on June 16, 2026.
• This transaction involved the sale of 887 shares of common stock at a weighted average price of $18.33 per share.
• The sale was to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) granted on December 4, 2024.
• This sale was executed under a pre-arranged contract consistent with Rule 10b5-1(c) for affirmative defense.
• Following the transaction, Kerr beneficially owns 169,155 shares, which includes 145,313 unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction is a standard, pre-planned sale to cover tax obligations and does not reflect a discretionary decision to divest based on company performance.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, indicating pre-planned and non-discretionary sales.
• The sale was specifically to cover tax withholding obligations, a common and expected event upon RSU vesting.

Negatives

• A portion of the reporting person's holdings were sold, reducing their direct ownership.

Risks

• The sale price was within a range of $18.00 to $18.70, indicating potential market price fluctuations at the time of sale.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it pertains to a specific insider transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for public company insiders, detailing changes in their beneficial ownership. This specific filing indicates a standard practice of selling shares to cover tax liabilities associated with equity compensation, which is common across the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: The sale of 887 shares by a key executive is unlikely to have a significant impact on the company's share price, especially given it's a pre-planned transaction for tax purposes.

Key Dates

Keywords

Dyne Therapeutics, Form 4, Insider Trading, Stock Sale, RSU Vesting, Tax Withholding, Douglas Kerr, Rule 10b5-1